| Date Filed | Type | Description |
| 04/08/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/17/2016 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 02/16/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/11/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/05/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 02/05/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 02/05/2016 |
RW
| Form RW - Registration Withdrawal Request |
| 02/05/2016 |
RW
| Form RW - Registration Withdrawal Request |
| 02/05/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/05/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/04/2016 |
4
| Thomas Robert (Director) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Paid exercise price by delivering 7,145 shares
@ $5.62, valued at
$40.2k
Disposed/sold 9,378 shares
@ $0
Disposed/sold 90,116 shares
@ $0
Exercised 16,523 options to buy
@ $2.43, valued at
$40.2k
|
|
| 02/04/2016 |
4
| Moore Daniel Jeffrey (Director) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Paid exercise price by delivering 6,772 shares
@ $5.62, valued at
$38.1k
Disposed/sold 8,889 shares
@ $0
Exercised 15,661 options to buy
@ $2.43, valued at
$38.1k
|
|
| 02/04/2016 |
4
| O'Quinn Shari L (VP Clinical/Regulatory Affairs) has filed a Form 4 on TriVascular Technologies, Inc. |
| 02/04/2016 |
4
| Jayaraman Vivek K (VP Global Sales and Marketing) has filed a Form 4 on TriVascular Technologies, Inc. |
| 02/04/2016 |
4
| New Enterprise Associates 12, Limited Partnership (10% Owner) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Disposed/sold 3,943,269 shares
@ $0 |
|
| 02/04/2016 |
4
| Kramer Michael R (CFO) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Paid exercise price by delivering 6,561 shares
@ $5.62, valued at
$36.9k
Disposed/sold 8,439 shares
@ $0
Paid exercise price by delivering 7,238 shares
@ $5.62, valued at
$40.7k
Disposed/sold 8,794 shares
@ $0
Disposed/sold 92,309 shares
@ $0
Exercised 15,000 restricted stock units
@ $0
Exercised 16,032 options to buy
@ $2.43, valued at
$39k
|
|
| 02/04/2016 |
4
| Scopa James Paul (Director) has filed a Form 4 on TriVascular Technologies, Inc.|
Txns:
| Disposed/sold 1,776,692 shares
@ $0 |
|
| 02/04/2016 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 02/03/2016 |
8-K
| Quarterly results |
| 01/25/2016 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/07/2016 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 11/09/2015 |
10-Q
| Quarterly Report for the period ended September 30, 2015 |
| 11/09/2015 |
8-K
| Quarterly results |
| 10/26/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger, among Endologix, Inc., TriVascular Technologies, Inc., and Teton Merger Sub Inc. Schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request",
"Form of Voting Agreement, by and among Endologix, Inc., Teton Merger Sub Inc. and certain stockholders of TriVascular Technologies, Inc",
"Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders" |
|
| 10/26/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 08/05/2015 |
10-Q
| Quarterly Report for the period ended June 30, 2015 |
| 08/04/2015 |
8-K
| Quarterly results |
| 08/04/2015 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Second Amended and Restated Term Loan Agreement, by and among TriVascular Technologies, Inc., TriVascular, Inc., TriVascular Sales LLC, TriVascular Canada, LLC and Capital Royalty Partners II L.P., Parallel Investment Opportunities Partners II L.P., Capital Royalty Partners II—Parallel Fund “A” L.P., Capital Royalty Partners II (Cayman) L.P. and Capital Royalty Partners II—Parallel Fund “B” (Cayman) L.P.",
"Form of Registration Rights Agreement, by and among TriVascular Technologies, Inc. and Capital Royalty Partners II L.P., Parallel Investment Opportunities Partners II L.P., Capital Royalty Partners II—Parallel Fund “A” L.P., Capital Royalty Partners II (Cayman) L.P. and Capital Royalty Partners II—Parallel Fund “B” (Cayman) L.P" |
|
| 05/29/2015 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 05/27/2015 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/06/2015 |
10-Q
| Quarterly Report for the period ended March 31, 2015 |
| 05/05/2015 |
8-K
| Quarterly results |
| 04/14/2015 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
| 04/08/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
|